Sydney Lupkin
From this contributor
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Eight pharmaceutical companies more than doubled their lobbying spending in the first three months of 2017.
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Health companies gave generously to President Trump’s inauguration
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events.
Health companies gave generously to President Trump’s inauguration
Trump’s choice to run food and drug agency has pharma connections
Scott Gottlieb, nominated to lead the U.S. Food and Drug Administration has deep ties to industry, and has worn many other hats in his career.
Trump’s choice to run food and drug agency has pharma connections
Senators call for investigation into possible abuses of Orphan Drug Act
Building on weeks of mounting pressure to address high prescription drug prices, three influential U.S. senators have asked the government’s accountability arm to probe the orphan drug program for potential misuse.
Senators call for investigation into possible abuses of Orphan Drug Act
Former head of FDA concerned about faster drug approvals
Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration's plans to speed up drug approvals and dramatically reduce regulations at the agency.
Former head of FDA concerned about faster drug approvals
Explore more from The Transmitter
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
Can neuroscientists decode memories solely from a map of synaptic connections?
Five experts discuss the progress, possibilities and hurdles of decoding a “nontrivial” memory from an organism just by analyzing its brain connectivity patterns.
Can neuroscientists decode memories solely from a map of synaptic connections?
Five experts discuss the progress, possibilities and hurdles of decoding a “nontrivial” memory from an organism just by analyzing its brain connectivity patterns.